News

Quintiles' Pike: Innovation is the path to growth

Speaking to local business leaders in Research Triangle Park, Quintiles CEO Tom Pike said the life sciences' industry's biggest obstacle is comfort, as long-running biases in medicine can stave off innovation.

U.K. outfit bets on early-phase outsourcing

Cresset, a British provider of drug-discovery services, has faith in the market for early-phase work, and the company has expanded its staff and headquarters to prepare for an uptick in demand.

CRO Psi jumps into India

Switzerland's Psi is reaching into India's clinical research market, opening up shop in the country and continuing its global expansion.

Vince & Associates eyes gastro trials with expansion

Kansas CRO Vince & Associates, fresh from its private equity buyout, has expanded its endoscopy capabilities, beefing up its technology to attract more early-phase studies of gastrointestinal therapies.

Study: CROs dishing out bonuses to halt high turnover

High employee turnover rates have long been a fact of life in the CRO world, but more and more companies are being proactive, amping up their bonus offerings to lure and retain talent, according to study.

Icon dives into adaptive trial monitoring

The FDA is encouraging drugmakers to embrace new methods of monitoring for clinical trials, and Icon is betting its latest offering can streamline how sponsors deal with study sites and save money in the process.

Risk-based monitoring could be a boon to CROs

Now that the FDA is encouraging drugmakers to consider risk-based monitoring for clinical trials, CROs that have already invested in adaptive trials could stand to benefit.

Boehringer pulls plug on VA commercial plant

After months of fretting over API capacity, Boehringer Ingelheim is planning to shutter en masse its Petersburg, VA, commercial plant, putting 240 employees out of a job.

Express Scripts sells CRO biz to private equity outfit

Bracket, the pharma contracting arm of Express Scripts, is now the property of Parthenon Capital Partners, the latest private equity takeover in a fast-consolidating industry.

How can early-phase CROs stay afloat in a changing market?

They don't make compounds like the used to--or at least at the same rate. And with fewer and fewer early-stage molecules moving through pipelines, some discovery-focused CROs have been left in the lurch.

WuXi ratchets up expectations after banner quarter

WuXi PharmaTech, China's largest CRO, is counting on the burgeoning drug development market in its home country to deliver a big 2013, stretching its annual revenue guidance after another quarterly boost.

Quintiles buying Novella with eye on emerging biotechs

Quintiles is back on the buyer's block for the first time since going public, agreeing to scoop up oncology-focused CRO Novella Clinical for an undisclosed sum.

AMRI's shares crater as partner Bristol-Myers ditches depression drug

Bristol-Myers Squibb is calling it quits on a depression drug it was working on with Albany Molecular Research, and investors sent the contractor's shares into a plunge as its CEO preached patience.

Covance offers service to keep contracts under control

Covance has launched a managed markets service platform designed to help its biopharma and medical device clients deal with managed care organizations, group purchasing outfits, federal and state programs and wholesalers.

Icon signs up to boost Taiwan's stake in drug development

CRO Icon has signed a deal with the National Taiwan University Hospital, lending its weight in clinical research to help make local trials faster and more reliable.

ScinoPharm, Sundia team up in China

Taiwanese contract manufacturer ScinoPharm and Chinese CRO Sundia MediTech are pooling their resources to cash in on the demand for outsourced services in China.

Parexel bets big on the future as revenue swells

Parexel turned in another quarter of double-digit sales growth, riding increases in IT and consulting revenue to a huge year-over-year jump in profits.

AMRI swings to red despite another sales jump

AMRI watched a spike in costs erode its solid second-quarter sales, but the the contract drugmaker still believes it can churn out an annual profit and boost its revenue.

InVentiv takes aim at blockbusters with biosimilar deal

CRO inVentiv Health is teaming up with Oncobiologics to develop biosimilars of some of world's top-selling treatments, signing up to helm clinical trials and help get the knockoffs on the market.

Clinipace reaches into the north with CRO partnership

Clinipace has struck a deal with Finland's Medfiles, allowing the North Carolina CRO to offer its clients services across the Nordics and Baltic countries.